Summary
Abbott Laboratories (ABT) has filed an 8-K report on October 16, 2024, to announce its third-quarter 2024 financial results. The report primarily references a press release issued on October 16, 2024, which details these results and includes the use of various non-GAAP financial measures. Investors should note that these non-GAAP measures are presented to offer a clearer view of ongoing business performance by excluding items such as acquisition-related expenses, restructuring costs, and fair value adjustments. While Abbott's management believes these non-GAAP metrics provide valuable insights, they are intended to supplement, not replace, GAAP-based financial measures. The filing highlights the company's emphasis on providing transparency into its operational performance beyond standard accounting practices, allowing for a better evaluation of core business trends. Investors are encouraged to review the provided press release for the specific financial figures and further details on the non-GAAP adjustments.
Key Highlights
- 1Abbott Laboratories announced its third-quarter 2024 financial results on October 16, 2024, via an 8-K filing.
- 2The results are detailed in a press release furnished as Exhibit 99.1.
- 3The company utilized non-GAAP financial measures in its earnings announcement.
- 4Non-GAAP measures exclude items such as acquisition costs, restructuring, and fair value adjustments.
- 5Abbott's management believes these non-GAAP measures offer better insight into ongoing business performance.
- 6Investors are advised to consider non-GAAP measures alongside GAAP financial results.